Pilgrim Builds Hardware for the Biosecurity Frontier

Biology has a handoff problem. A discovery can perform beautifully on a bench, then spend years crossing the distance between research, manufacturing, procurement, and the field where somebody actually needs it.

Pilgrim is building a defense-biotechnology company around collapsing that distance. The Redwood City company combines biology, engineering, manufacturing, operations, and government deployment, with hardware designed for biological-threat detection, battlefield trauma, and medical logistics.

Founder and CEO Jake Adler describes the ambition as building battlefield-ready biotechnology. The larger wager is that national-security biology needs an integrated prime, not another promising invention waiting for somebody else to carry it out of the lab.

What Pilgrim Builds

Pilgrim's current portfolio spans three hardware programs. ARGUS is an autonomous biosurveillance platform for collecting airborne biological material, screening for known and novel threats, and analyzing results on-device. KINGSFOIL is intended to control massive hemorrhage when medical evacuation is delayed or denied. BIFROST is designed to preserve lifesaving cargo moving through contested environments.

The three products sit at different points in the same operational chain. ARGUS is about knowing that a biological threat may be present. KINGSFOIL is about keeping an injured person alive when the normal care pathway breaks. BIFROST is about keeping medicine usable while the supply route becomes hostile. Pilgrim is organizing the company around the places where biology collides with time, distance, and damaged infrastructure.

ARGUS has the most detailed public specifications. Pilgrim lists a time to result below 60 minutes, a weight of 50 lb, dimensions of 17 by 21 by 26 inches, a collection rate of 325 liters per minute, and UV LIF, qPCR, and sequencing detection modes. The system also includes edge compute rated at 157 TOPS.

Those are company specifications, not independent proof of field performance. Sensitivity, specificity, false-positive behavior, reliability, data governance, and operating cost will matter more than a clean specification sheet once the product enters a noisy airport, base, hospital, port, or farm.

Pilgrim Is Building Beyond the Laboratory

Pilgrim's most important design decision may be organizational. Its leadership and careers page says the company brings biology, engineering, and manufacturing under one roof to move discoveries from laboratory to field.

That structure recognizes an uncomfortable truth about deep technology. A laboratory result does not automatically become a manufacturable device. A device does not automatically survive deployment. A successful deployment does not automatically become a program that a government agency can fund, procure, maintain, and trust.

Pilgrim is trying to own more of those handoffs. Its current careers framework spans engineering, science, operations, and government. Engineering owns hardware from design through manufacturing and field deployment. Science translates biological research into capability. Operations supports production and deployment. Government work turns national priorities into programs.

The model can reduce coordination loss, but it also concentrates execution risk. Pilgrim has to be competent across science, hardware, manufacturing, quality, procurement, and institutional adoption at the same time. Integration is an advantage only when each layer works.

Leadership Matches the Deployment Problem

Jake Adler is Pilgrim's founder and CEO. Pilgrim says Adler is a Thiel Fellow who led a Class II brain-computer interface through FDA review and built a garage nanofabrication setup for bioelectronics and metasurfaces. His background connects hands-on hardware work with regulated medical technology.

Fernando Soto, Head of Science, holds a Ph.D. in nanoengineering and completed Stanford postdoctoral work in viral capture and medical devices. Mauricio Moel, Head of Operations, previously sold a company to Nestlé and helped scale AgelessRX. Todd Ritter, Head of Government, previously served as a U.S. Air Force Force Protection Chief and, according to Pilgrim, built and deployed a $600M-plus military biodefense program using qPCR across 230 installations.

The lineup is revealing. Pilgrim is not treating scientific discovery as the finish line. The company has assigned senior ownership to science, operations, and government because a defense-biotechnology product can fail in any one of those lanes.

The Market Is Early Warning and Human Survival

Defense technology investment often follows the machine: autonomy, drones, software, sensors, and weapons. Pilgrim is focused on what happens to people and institutions when biological risk enters the environment or the normal chain of medical support breaks.

That market extends beyond a single defense program. Pilgrim identifies defense, homeland security, and public health as ARGUS applications. Earlier biological warning could matter at military installations, airports, hospitals, ports, farms, laboratories, and other critical sites.

The CDC Laboratory Response Network shows why faster detection still has to connect with confirmatory infrastructure. State, local, federal, and military laboratories coordinate to respond to biological and chemical emergencies. A field device may start the clock sooner, but validation, authority, communication, and response determine whether the warning changes an outcome.

Pilgrim's opportunity is therefore larger than selling hardware. The company has to fit products into the institutions responsible for acting on them. That demands technical performance, secure data handling, repeatable manufacturing, training, maintenance, procurement, and a clear response protocol after an alert.

Capital Is Funding an Integrated Biology Prime

Pilgrim raised a reported $25M Seed round led by Buckley Ventures at a reported $150M valuation in September 2026. The company had previously raised a $4.3M round reported in 2025, led by Cantos. Pilgrim's current investor roster also includes Thiel Capital, Conviction, Shine Capital, Mantis, Refactor Capital, and Magellan, alongside a group of technology founders and operators.

The latest financing gives Pilgrim more room to build the company around its product thesis. A 20,000-square-foot Redwood City facility, an announced CDC biosurveillance agreement, and company-reported federal deployments are signals that the work is moving beyond a prototype. The terms and performance of those programs remain private, so they should be read as operating evidence rather than independent validation.

DevCuration's Funding Announcement examined the obligation created by the new round. The Company Spotlight reveals the broader company behind that obligation: Pilgrim is trying to make biology behave like deployable infrastructure across sensing, medicine, logistics, and government programs.

Hiring Shows Where the Company Must Get Stronger

Pilgrim's hiring page points builders toward engineering, science, operations, and government roles, with Redwood City anchoring the technical and operating work and Washington anchoring government execution. The company also advertises a $20,000 referral award after a referred hire completes four months.

The signal is not that Pilgrim has a careers page. Every startup has one. The signal is the mix of capabilities it needs to assemble. A biology prime cannot be built by researchers handing a prototype to a procurement team at the end. The manufacturing, program, policy, and field-deployment decisions have to shape the product much earlier.

Pilgrim matters because it is making that organizational bet explicit. If the company succeeds, the advantage will not belong to one sensor, dressing, or transport system. It will come from carrying biology across the hard distance between a discovery and the moment an institution depends on it.